2021 Chemotherapy Pharmaceutical Companies 
Pharmaceutical Technology
MARCH 14, 2023
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry. Several platinum-based drugs such as cisplatin, carboplatin and oxaliplatin are widely used in cancer therapy.
Pharmaceutical Technology
MARCH 14, 2023
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry. Among its key functions, it interacts with nucleic acids and enzymes during their synthesis and function.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 17, 2023
In 2021, the FDA granted Amgen’s (NASDAQ:AMGN) non-small cell lung cancer (NSCLC) drug Lumakras (sotorasib) an expedited approval, making it the first FDA-approved KRAS inhibitor. In 2021, Amgen agreed to conduct a Phase II study (NCT04933695), which is supposed to complete in May 2024, according to Clinicaltrials.gov.
pharmaphorum
OCTOBER 3, 2022
It is therefore an interesting development that sugemalimab was given an Innovation Passport in NICE’s Innovative Licensing and Access Pathway (ILAP) in October 2021. Single Technology Appraisal: Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer ID4001. National Institute for Clinical Excellence.
Roots Analysis
DECEMBER 11, 2022
Antibody drug conjugates (ADCs) are an upcoming class of targeted therapeutic agents that have garnered the attention of pharmaceutical companies, and academic / research institutions across the world. Examples of recently approved ADCs include Enhertu (2021), Blenrep (2020) and Polivy (2020).
pharmaphorum
JANUARY 5, 2022
The decision – which comes after an earlier rejection by NICE in March 2021 – covers Lynparza’s approval for prostate cancer cases with BRCA1 or BRCA2 mutations that has spread (metastasised) to other parts of the body and has relapsed after prior treatment with the hormonal drugs abiraterone or enzalutamide.
Pharmaceutical Technology
JUNE 16, 2023
Designated as BG01-2202, this latest trial will be an open-label, randomised, controlled clinical study of UTD1 versus chemotherapy drug docetaxel. A Phase III study to evaluate UTD1 versus docetaxel in patients that have failed chemotherapy with a platinum-containing regimen is also currently underway in China. ORR, 81.0%
Expert insights. Personalized for you.
52 
Let's personalize your content